Physician profile
Raphael E Albert
NPI 1457414310
$3,306.74
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $543 · 2021: $490 · 2022: $108 · 2023: $577 · 2024: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $437.40 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $430.98 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Novo Nordisk INC | $396.63 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $313.17 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abiomed | $279.57 | 2023-2024 | Impella |
| Amgen INC. | $265.93 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.34 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Amarin Pharma, INC. | $127.23 | 2019-2021 | |
| Pfizer INC. | $123.53 | 2019-2024 | |
| Abbvie INC. | $110.24 | 2021-2022 | |
| Exact Sciences Corporation | $76.42 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $67.94 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Eisai INC. | $50.18 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $46.18 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $40.00 | 2024 | Watchman Flx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.82 | 2024 | Voquezna |
| Vyera Pharmaceuticals, LLC | $28.29 | 2019 | |
| Inspire Medical Systems, INC. | $26.84 | 2023 | Inspire |
| Ironwood Pharmaceuticals, INC | $26.75 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.01 | 2019-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $24.20 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $19.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.48 | 2019 | |
| Astellas Pharma US INC | $17.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.78 | 2021 | |
| Dexcom, INC. | $15.43 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $14.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.20 | 2019 | |
| Hikma Pharmaceuticals USA | $12.72 | 2019 | |
| Allergan, INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.